Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis
- PMID:23722644
- DOI: 10.1378/chest.13-0675
Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis
Abstract
Background: Clinical studies have suggested an association between bisphosphonate use and the onset of atrial fibrillation (AF). However, data on the risk of developing AF, stroke, and cardiovascular mortality with the use of bisphosphonate are conflicting. The objective of this study was to evaluate the risk of serious AF (events that required hospital admission), stroke, and cardiovascular mortality with the use of bisphosphonates through a systematic review of the literature.
Methods: We searched the PubMed, CENTRAL, and EMBASE databases for observational studies and randomized controlled trials (RCTs) on the use of bisphosphonates from 1966 to April 2012 that reported the number of patients who developed serious AF, stroke, and cardiovascular mortality at follow-up. The random-effects Mantel-Haenszel test was used to evaluate relative risk-adverse cardiovascular outcomes with the use of bisphosphonates.
Results: Six observational studies (n = 149,856) and six RCTs (n = 41,375) were included for analysis. On pooling observational studies, there was an increased risk of AF (OR, 1.27; 95% CI, 1.16-1.39) among bisphosphonate users. Further, analysis of RCTs revealed a statistically significant increase in the risk of serious AF (OR, 1.40; 95% CI, 1.02-1.93) and no increase in the risk of stroke (OR, 1.07; 95% CI, 0.85-1.34) or cardiovascular mortality (OR, 0.92; 95% CI, 0.68-1.26) with the use of bisphosphonates.
Conclusions: Evidence from RCTs and observational studies suggests a significantly increased risk of AF requiring hospitalization, but no increase in risk of stroke or cardiovascular mortality, with the use of bisphosphonate.
Similar articles
- Bisphosphonates and risk of cardiovascular events: a meta-analysis.Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC.Kim DH, et al.PLoS One. 2015 Apr 17;10(4):e0122646. doi: 10.1371/journal.pone.0122646. eCollection 2015.PLoS One. 2015.PMID:25884398Free PMC article.
- Risk of atrial fibrillation with use of oral and intravenous bisphosphonates.Sharma A, Einstein AJ, Vallakati A, Arbab-Zadeh A, Walker MD, Mukherjee D, Homel P, Borer JS, Lichstein E.Sharma A, et al.Am J Cardiol. 2014 Jun 1;113(11):1815-21. doi: 10.1016/j.amjcard.2014.03.008. Epub 2014 Mar 15.Am J Cardiol. 2014.PMID:24837258Review.
- Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.Loke YK, Jeevanantham V, Singh S.Loke YK, et al.Drug Saf. 2009;32(3):219-28. doi: 10.2165/00002018-200932030-00004.Drug Saf. 2009.PMID:19338379Review.
- Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies.Mak A, Cheung MW, Ho RC, Cheak AA, Lau CS.Mak A, et al.BMC Musculoskelet Disord. 2009 Sep 21;10:113. doi: 10.1186/1471-2474-10-113.BMC Musculoskelet Disord. 2009.PMID:19772579Free PMC article.
- Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis.Bhuriya R, Singh M, Molnar J, Arora R, Khosla S.Bhuriya R, et al.Int J Cardiol. 2010 Jul 23;142(3):213-7. doi: 10.1016/j.ijcard.2009.11.041. Epub 2010 Jan 3.Int J Cardiol. 2010.PMID:20051297Review.
Cited by
- Increased risk of stroke among hip fracture patients: a nationwide cohort study.Tsai CH, Lin CL, Hsu HC, Chung WS.Tsai CH, et al.Osteoporos Int. 2015 Feb;26(2):645-52. doi: 10.1007/s00198-014-2919-7. Epub 2014 Oct 10.Osteoporos Int. 2015.PMID:25300529
- Bisphosphonates and risk of cardiovascular events: a meta-analysis.Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC.Kim DH, et al.PLoS One. 2015 Apr 17;10(4):e0122646. doi: 10.1371/journal.pone.0122646. eCollection 2015.PLoS One. 2015.PMID:25884398Free PMC article.
- Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements.Tisdale JE, Allen MR, Overholser BR, Jaynes HA, Kovacs RJ.Tisdale JE, et al.J Cardiovasc Electrophysiol. 2015 Jun;26(6):671-7. doi: 10.1111/jce.12641. Epub 2015 Mar 31.J Cardiovasc Electrophysiol. 2015.PMID:25684326Free PMC article.
- Saving bones without risking brain-bisphosphonates and risk of stroke: matched case-control study.Asghar ZB, Godoy Caballero A, Pathirannehelage S, Williams J, McKay S, Grassby P, de Lusignan S, Niroshan Siriwardena A.Asghar ZB, et al.Osteoporos Int. 2019 Sep;30(9):1845-1854. doi: 10.1007/s00198-019-05045-z. Epub 2019 Jun 17.Osteoporos Int. 2019.PMID:31214750
- The Association between Treatment with Bisphosphonates and the Risk of Atrial Fibrillation: A Meta-Analysis of Observational Studies.Park JH, Ko HJ.Park JH, et al.Korean J Fam Med. 2022 Jan;43(1):69-76. doi: 10.4082/kjfm.21.0110. Epub 2022 Jan 20.Korean J Fam Med. 2022.PMID:35130642Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous